SThe Effects of Melatonin on GERD Symptoms
Recruitment status was Not yet recruiting
We hypothesize that melatonin as compared to PPI and to placebo, improves GERD symptoms by decreasing esophageal acid exposure and esophageal acid sensitivity in GERD. We hypothesize that melatonin as compared to PPI and to placebo reduce the frequency and duration of transient lower esophageal sphincter relaxations (TLESRs). In addition we hypothesize that melatonin as compared to PPI and to placebo improves quality of life and quality of sleep of GERD patients.
Gastroesophageal Reflux Disease
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||The Effects of Melatonin on GERD Symptoms and Esophageal Acid Exposure|
- This study will test the efficacy of melatonin (10 mg once a day) as compared to standard dose PPI (omeprazole 20 mg once a day) and placebo on different subjective and objective parameters of 150 patients with GERD. [ Time Frame: 3 years ]
- To determine the effect of melatonin versus standard-dose PPI versus placebo on frequency and duration of TLESRs. [ Time Frame: 3 years ]
|Study Start Date:||October 2008|
|Estimated Study Completion Date:||January 2011|
Melatonin treatment group
4 mg of Melatonin once a day for 3 months
Active Comparator: B
Omeprazole 20 mg once a day for 3 months
omeprazole 20 mg once a day
Other Name: Omepradex
Placebo once a day for 3 months
Placebo once a day
Other Name: Placebo
Background: Gastroesophageal reflux disease (GERD) is a chronic, persistent and common medical problem. The standard of care for GERD includes chronic administration of acid-suppressive drugs. However, clinical failure in GERD is increasingly reported.
Aim: To determine the efficacy of treatment with melatonin as compared to standard dose proton pump inhibitor (PPI) as compared to placebo in patients with GERD.
Study objectives:  To compare the degree of GERD symptoms improvement and esophageal acid sensitivity before and after treatment.  To determine the effect of treatment on the % total, upright and supine time pH <4 using 24-hour esophageal pH monitoring.  To determine the effect of treatment on frequency and duration of lower esophageal sphincter relaxation.  To compare the quality of life and quality of sleep in GERD patients before and after treatment.
Methods: This is a randomized, double blind, parallel groups study of 150 patients with GERD. Patients with classic heartburn symptoms (heartburn and/or regurgitation) and normal upper endoscopy from the gastroenterology department at Rabin Medical Center will be enrolled into the study. At baseline, all enrolled patients will have 24-hour esophageal pH monitoring and a modified acid perfusion test to assess the extent of distal esophageal acid exposure and esophageal acid sensitivity, respectively. Patients will be evaluated by a demographics questionnaire, the GERD Symptom Questionnaire, the Quality of Sleep questionnaire and the SF-36. Baseline urinary excretion of the main melatonin metabolite, 6-sulfatoxymelatonin (6SMT) will be assessed in all subjects at baseline. Patients will be randomized to either melatonin or standard dose PPI or placebo over a period of 4 weeks. In addition patients will fill a diary on a daily basis that documents severity and frequency of GERD-related symptoms. Symptom score (frequency x severity) will be calculated for previous 7 days at baseline and at the end of treatment in all groups. After 4 weeks of treatment, patients will undergo a second 24-hour esophageal pH monitoring, a modified acid perfusion test and will complete the GERD Symptom Questionnaire, the Quality of Sleep Questionnaire and the SF-36.
Implications: This study will determine if melatonin decreases GERD symptoms, acid esophageal exposure and improves quality of life and sleep in patients with GERD. Furthermore, if there will be a significant clinical response to melatonin it will be possible to add this compound to the treatment armamentum of GERD.
|Contact: Ram M Dickman, MD||03:firstname.lastname@example.org|
|Contact: Tami Lederfine||03:9377040||Tamila@clalit.org.il|
|Rabin Medical Center, Beilinson Hospital||Not yet recruiting|
|Petach Tikva, Israel, 49100|
|Principal Investigator: Ram M Dickman, MD|
|Principal Investigator:||Ram M Dickman, MD||Rabin Medical Center|